An independent advisory committee to the Food and Drug Administration will decide on Thursday whether to recommend an RSV vaccine for infants.

If eventually approved, the shot, which is made by Pfizer and administered to pregnant mothers, would be the first RSV vaccine for infants in the U.S.

“Before the pandemic, RSV was the No. 1 cause of infant hospitalization in the United States, so this is a big deal,” said Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children’s Hospital. Levy is a temporary voting member of the FDA panel but isn’t involved in Thursday’s vote.